Two biotechs that don't have approved drugs yet. One clear winner.
News & Analysis: Intellia Therapeutics
First-quarter earnings results from three gene-editing companies gave Wall Street analysts pause.
NTLA earnings call for the period ending March 31, 2019.
The future of treating disease might be gene editing, and these five stocks have the most promising technologies.
Which stock wins in a matchup between two leading gene-editing biotechs?
The future of medicine involves the precise engineering of human cells. Turns out, that future may not include that promising CRISPR technique.
The gene-editing pioneer was an easy target during the end-of-the-year market sell-off.
The three gene-editing pioneers had mixed results last year, but each has big plans for the year ahead.
It was a busy month for gene editing stocks, which suffered from both CRISPR-specific news and the broader stock market's fall.
Which stock wins in a matchup between these two biotechs focused on CRISPR gene editing?